2022
Long-term effects of increased adoption of artemisinin combination therapies in Burkina Faso
Zupko R, Nguyen T, Somé A, Tran T, Gerardin J, Dudas P, Giang D, Tran K, Wesolowski A, Ouédraogo J, Boni M. Long-term effects of increased adoption of artemisinin combination therapies in Burkina Faso. PLOS Global Public Health 2022, 2: e0000111. PMID: 36962300, PMCID: PMC10021447, DOI: 10.1371/journal.pgph.0000111.Peer-Reviewed Original ResearchMultiple first-line therapiesFirst-line therapyTreatment failure rateArtemether-lumefantrineFalciparum malariaCombination therapyLong-term effectsEqual long-term outcomesLower treatment failure rateUncomplicated Plasmodium falciparum malariaMajor global public health concernGlobal public health concernPlasmodium falciparum malariaP. falciparum malariaLong-term outcomesArtemisinin combination therapyP. falciparum transmissionPublic health concernMalaria settingsTreatment failureFailure rateHigh burdenTreatment efficacyACT useDrug resistance
2020
Efficacy of artemether-lumefantrine and artesunate-amodiaquine as first line therapy of uncomplicated malaria in Burkina Faso, 11 years after policy change
Zongo I, Compaoré Y, Nikiéma F, Zongo M, Barry N, Somé F, Kaboré N, Ouédraogo J. Efficacy of artemether-lumefantrine and artesunate-amodiaquine as first line therapy of uncomplicated malaria in Burkina Faso, 11 years after policy change. Pan African Medical Journal 2020, 35: 68. PMID: 32537072, PMCID: PMC7250195, DOI: 10.11604/pamj.2020.35.68.20849.Peer-Reviewed Original ResearchConceptsFirst-line therapyLine therapyUncomplicated malariaPolymerase chain reactionTreatment efficacyEarly treatment failureGood tolerability profileFirst-line treatmentParasitological responsePrimary endpointTolerability profileArtemether-lumefantrineTreatment failureLine treatmentASAQ groupDay 28Better efficacyBurkina FasoTherapyMalariaEfficacyChain reactionCompletion ratesTreatmentDays